Eltroxin Administration to Patients With Extremely Low T4 Values in the Intensive Care Unit
Launched by MEIR MEDICAL CENTER · Nov 23, 2023
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating whether a medication called eltroxin can help patients in the intensive care unit (ICU) who have extremely low levels of a thyroid hormone called T4. Low T4 levels can happen in critically ill patients and might be linked to a higher risk of serious complications or death. While doctors usually don't test thyroid levels in ICU patients unless there's a known thyroid problem, this study aims to focus on those with very low T4 levels, as they face a particularly high risk. Researchers want to find out if giving eltroxin to these patients can improve their chances of recovery.
To participate in this trial, you must be between 18 and 99 years old and have been admitted to the general ICU for any reason between January 2016 and November 2023. You should also have had a T4 test result that was lower than normal, specifically less than half of the normal lower limit. However, if you had a known thyroid problem or were taking eltroxin before your hospital stay, you wouldn't be eligible. By joining this trial, participants will help researchers better understand how to treat critically ill patients with low thyroid hormone levels.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: All patients aged 18--99 who were admitted to the general intensive care unit from January 2016 to November 22, 2023 for any reason, and who during their hospitalization in the intensive care unit had lower than normal T4 levels measured. It is about 350 patients. Of these, we will specifically examine the group of patients for whom an extremely low level of T4 was measured (less than 50% of the lower limit of the norm).
- • -
- • Exclusion Criteria: Patients who were known to have a chronic thyroid dysfunction prior to their hospitalization in the unit, patients who were regularly treated with eltroxin prior to their hospitalization
- • -
About Meir Medical Center
Meir Medical Center is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. As a prominent sponsor of clinical studies, Meir Medical Center is committed to fostering collaboration among healthcare professionals, researchers, and patients to explore new therapies and treatment modalities. With a focus on ethical practices and patient safety, the center aims to contribute significantly to the scientific community while enhancing the quality of care provided to its diverse patient population. Through its robust infrastructure and multidisciplinary approach, Meir Medical Center stands at the forefront of medical innovation, driving progress in various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kfar Saba, , Israel
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported